This rapid and increasing uptake underscores the potential of LAMP1-based radiopharmaceuticals for imaging and therapeutic applications across a spectrum of human carcinomas, such as colon, breast, and prostate cancers [19]. Here, LAMP1 is linked to prostate carcinoma.